U.S. Capital Wealth Advisors LLC Acquires 44,707 Shares of Novo Nordisk A/S $NVO

U.S. Capital Wealth Advisors LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 93.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 92,695 shares of the company’s stock after purchasing an additional 44,707 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $5,144,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Bath Savings Trust Co lifted its holdings in Novo Nordisk A/S by 15.7% during the 3rd quarter. Bath Savings Trust Co now owns 26,004 shares of the company’s stock valued at $1,443,000 after purchasing an additional 3,521 shares during the last quarter. Voya Investment Management LLC increased its holdings in shares of Novo Nordisk A/S by 7.1% during the third quarter. Voya Investment Management LLC now owns 29,295 shares of the company’s stock worth $1,626,000 after buying an additional 1,930 shares in the last quarter. Mitchell & Pahl Private Wealth LLC raised its stake in shares of Novo Nordisk A/S by 8.6% in the third quarter. Mitchell & Pahl Private Wealth LLC now owns 14,957 shares of the company’s stock valued at $830,000 after acquiring an additional 1,180 shares during the last quarter. Dynamic Advisor Solutions LLC boosted its holdings in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 31,089 shares of the company’s stock worth $1,725,000 after acquiring an additional 331 shares in the last quarter. Finally, Fermata Advisors LLC bought a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $391,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $48.10 on Friday. The firm has a market cap of $214.76 billion, a price-to-earnings ratio of 13.98 and a beta of 0.67. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock has a 50-day moving average price of $49.84 and a 200 day moving average price of $57.59.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on NVO. Jefferies Financial Group assumed coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating on the stock. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Wednesday, December 3rd. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Finally, The Goldman Sachs Group reduced their target price on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $53.33.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo filed an NDA with the U.S. FDA for once?weekly CagriSema, a next?generation combination obesity injection that showed superior Phase III weight?loss results — a potential major booster to its obesity franchise if approved. Article Title
• Positive Sentiment: Novo is pursuing a higher 7.2 mg Wegovy dose after data showed stronger weight loss — this could help reclaim share versus rivals (e.g., Eli Lilly’s Zepbound) if approved and commercialized effectively. Article Title
• Positive Sentiment: Analyst/commentary pieces highlight upside from oral Wegovy development, supply?chain fixes and restructuring that could materially improve margins and growth if execution continues. Article Title
• Positive Sentiment: Kepler Capital initiated/maintained a buy view (reported coverage), giving some buy?side support to the shares. Article Title
• Neutral Sentiment: UBS reiterated a Neutral (Hold) rating and left its price target unchanged, signaling continued caution on competitive pressures despite product progress. Article Title
• Neutral Sentiment: Commentary pieces are reassessing Novo’s valuation after a steep, year?long share decline; some see a longer runway to recovery while others point to durable competitive threats. Article Title
• Negative Sentiment: Novo issued profit warnings and underwent a CEO change earlier this year and cut guidance, contributing to a large YTD share decline; that operational uncertainty remains a drag on investor confidence. Article Title
• Negative Sentiment: Shares recently dipped more than the broader market after earnings/profitability concerns were flagged; short?term volatility is likely to persist as investors weigh approvals vs competitive share losses. Article Title

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.